韩国与Beat AML队列年龄和性别调整后的基因组差异
该前瞻性多中心研究对603例韩国新诊断成人AML患者进行83个复发突变基因的靶向测序,并与Beat AML队列比较基因组谱。总体基因组景观保守,但RUNX1::RUNX1T1、CEBPA、GATA2、KIT和DDX41突变在韩国队列更常见,FLT3和NPM1突变较少,导致ELN 2022风险分类分布不同;调整关键临床变量后总生存差异不显著。
要点
- 韩国AML队列中RUNX1::RUNX1T1、CEBPA、GATA2、KIT和DDX41突变频率高于Beat AML队列。
- FLT3和NPM1突变在韩国队列中较Beat AML队列少见,ELN 2022风险分类分布存在差异。
- 多数DDX41改变为胚系(3.2%),提示需系统胚系评估以指导遗传咨询和供者选择。
核心结论
- 群体特异性基因组分布影响AML风险分层的临床应用,支持群体感知的精准医学策略。
研究设计与样本
- 前瞻性多中心研究纳入603例韩国新诊断成人AML患者,对83个复发突变基因进行靶向测序并整合临床注释。
- 基因组谱与Beat AML队列进行对比分析。
主要发现
- 总体基因组景观 broadly conserved,支持跨人群共享核心疾病生物学。
- RUNX1::RUNX1T1、CEBPA、GATA2、KIT和DDX41突变在韩国队列更常见,FLT3和NPM1突变较少见。
- 上述差异导致ELN 2022风险分类分布不同,对治疗分层有影响。
- 多数DDX41改变为胚系(3.2%)。
- 未调整总生存韩国队列看似更长,但调整关键临床变量后差异不显著。
关键数值与推荐
- 韩国队列中DDX41胚系改变占3.2%。
- 基因组差异对应ELN 2022风险分类的不同分布。
临床怎么用
- 在AML风险分层和治疗决策中应考虑人群特异性基因组分布。
- 对DDX41改变患者建议系统胚系评估,以指导遗传咨询和供者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic profiling plays a central role in risk stratification and therapeutic decision-making in acute myeloid leukemia (AML), yet the clinical implications of population-specific genomic architectures remain incompletely defined. We conducted a prospective, multicenter study of 603 adults with newly diagnosed AML in Korea, integrating targeted sequencing of 83 recurrently mutated genes with comprehensive clinical annotation across treatment intensities, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). For contextual comparison, genomic profiles were evaluated against the Beat AML cohort. The overall genomic landscape was broadly conserved, supporting shared core disease biology across populations. However, RUNX1::RUNX1T1, CEBPA, GATA2, KIT, and DDX41 mutations were more frequent in the Korean cohort, whereas FLT3 and NPM1 mutations were less common. These differences translated into a distinct distribution of European LeukemiaNet (ELN) 2022 risk categories, with implications for therapeutic stratification. Notably, most DDX41 alterations were germline (3.2%), highlighting the need for systematic germline evaluation with implications for genetic counseling and donor selection. Although unadjusted overall survival appeared longer in the Korean cohort, this difference was not significant after adjustment for key clinical variables. These findings indicate that population-specific genomic distributions reshape the clinical application of risk stratification and support population-aware precision medicine strategies in AML.
引用
- Kim M, Song IC, Park J, et al. Age- and sex-adjusted genomic differences between Korean and Beat AML cohorts. Blood Adv. 2026. PMID: 42710088. doi:10.1182/bloodadvances.2026020609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。